Sildenafil, sold under the brand name Viagra among others, is a medication used to treat erectile dysfunction and pulmonary arterial hypertension.
Facts
Drug ClassPhosphodiesterase type 5 (PDE5) inhibitor 1 Mechanism of ActionBlocks phosphodiesterase 5 (PDE5), preventing breakdown of cyclic guanosine monophosphate (cGMP), leading to smooth muscle relaxation and increased blood flow. 1 Approved UseTreats erectile dysfunction and pulmonary arterial hypertension. 1 First Approved / Isolated Year Significant RiskHeadaches, heartburn and flushed skin; rare vision or hearing loss and priapism; dangerous when combined with nitrate medications. 1 Classification
Approval Status ATC ClassSourced to the subject's own accountG: Genito-Urinary System and Sex Hormones 2 Route of Administration Sources
1. Sildenafil (Wikipedia)
Wikimedia FoundationLead section
used to treat erectile dysfunction and pulmonary arterial hypertension
Infobox, drug class
PDE5 inhibitor
Mechanism of action section
blocks phosphodiesterase 5 (PDE5)
History section
The drug was patented in 1996, approved for use in erectile dysfunction by the FDA on 27 March 1998, becoming the first oral treatment approved to treat erectile dysfunction in the United States, and offered for sale in the United States later that year.
Adverse effects section
dangerous when combined with nitric oxide donors like nitroglycerin
- Regulatory approval status
View the Source 2. Anatomical Therapeutic Chemical Classification System (Wikipedia)
WikipediaFirst-level anatomical group codes, Code GQuote, First-level anatomical group codes, Code G
Genito-urinary system and sex hormones
View the Source 3. Wikipedia
Wikipedia contributors, Wikimedia Foundationhttps://en.wikipedia.org/wiki/Sildenafil, lead sectionQuote, https://en.wikipedia.org/wiki/Sildenafil, lead section
ctive for treating sexual dysfunction in females. It can be taken orally, intravenously, or through the sublingual route. Onset when taken orally is typically within twenty minutes and lasts for about two hours.
View the Source Reader Challenges (0)
No disputes yet. Spotted an error or a better source? Open the first one.
Sign in to dispute this or suggest a correction.